Image Guided Thermal Therapy for Prostate Cancer

描述（由申请人提供）：2003年美国将诊断出大约190，000例前列腺癌新病例，今年将有30，400名美国男性死于前列腺癌。在美国，每年治疗前列腺癌的费用已达到17.2亿美元。虽然治疗前列腺癌有很多潜在的方法，但还没有出现一种“最佳治疗方法”，特别是对于早期前列腺癌的治疗。许多目前的疗法具有显著的伴随副作用和/或与它们相关的风险。出于这个原因，持续的努力已经朝着靶向早期定位的前列腺癌的微创手段的发展。 在第二阶段SBIR应用中，我们建议开发和测试磁共振成像（MRI）引导的局部前列腺癌激光消融系统。该系统将使用多个组织间激光输送探头来实现前列腺中的目标治疗体积。激光/计算机工作站基于治疗期间采集的实时温度敏感MR图像的处理来精确控制激光能量的沉积。先进的可视化和控制界面将允许用户在治疗期间指定和更新治疗目标。该系统将在前列腺癌的犬肿瘤模型中进行测试。根据我们之前的经验，我们相信该系统将通过微创、提高靶向准确性和反馈有关治疗进展的实时信息来改善前列腺癌的治疗。

DESCRIPTION (provided by applicant): Approximately 190,000 new cases of prostate cancer will be diagnosed in the U.S. in 2003, and this year 30,400 American men will die from prostate cancer. In the United States, the annual cost of treating prostate cancer has reached $1.72 billion. While there are a significant number of potential courses for treating prostate cancer, a single "best treatment" has not yet emerged, especially for managing early prostate cancer. Many current therapies have significant attendant side effects and/or risks associated with them. For this reason, continued effort has been expended toward development of minimally invasive means of targeting early-localized prostate cancer. In this Phase II SBIR application, we propose to develop and test a system for magnetic resonance imaging (MRI) guided laser ablation of localized prostate cancer. The system will use multiple interstitial laser delivery probes to effect targeted treatment volumes in the prostate. A laser/computer workstation precisely controls the deposition of laser energy based on processing of real-time temperature sensitive MR images acquired during therapy. An advanced Visualization and control interface will allow the user to specify and update therapeutic targets during treatment. This system will be tested in a canine tumor model of prostate cancer. Based on our prior experience, we believe that this system will offer an improvement in treatment of prostate cancer through minimally invasiveness, improved targeting accuracy, and feedback of real-time information about treatment progression.